The Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo will be held 14-18 November 2023 at the Salt Palace Convention Center in Salt Lake City, UT located in downtown Salt Lake City.
nRichDX will exhibit in booth #822 from Thursday to Saturday, November 16-18, 2023. Exhibits open at 11:15 AM (MT) on Thursday, November 16, and close at 1:30 PM on Saturday, November 18.
More information about AMP 2023, including specific exhibit hours and events is available at https://amp23.amp.org/.
The nRichDX booth will have the latest information on the Revolution Sample Prep System and associated products for pre-analytical sample handling for the isolation of liquid biopsy analytes, such as cfDNA, cfRNA, and cell-free total nucleic acid (cfTNA) extraction from plasma or urine samples. More information about nRichDX's new Revolution CTC Enrichment Kit (Epithelial) for the enrichment of circulating tumor cells (CTCs) originating from epithelial cells in whole blood will also be available.
AMP attendees working on liquid biopsy tests, extraction of cfDNA, cfRNA, circulating cell-free total nucleic acid (cfTNA), or the enrichment of CTCs, are specifically invited to visit the nRichDX booth to learn more about how higher yields of these analytes can increase assay performance through better sensitivity and earlier detection of targeted oncology markers.
About nRichDX:
nRichDX® is an emerging leader in sample prep solutions for isolating cfDNA, cfRNA, and enrichment of CTCs. The patented Revolution Sample Prep System™ is engineered specifically for liquid biopsy applications. It is the first and only high-yield, high-recovery, IVD-labeled sample prep platform that can process from 1 mL - 20 mL of plasma or urine sample volumes or up to 40 mL of blood in a single extraction using the company’s unique nRicher Cartridge™. Unlike other methods, Revolution sample prep doesn’t require yield-lowering eluate pooling, or sample transfer steps. nRichDX helps solve one of precision medicine’s greatest problems – – inaccurate or incomplete diagnostic results for liquid biopsy-based applications due to insufficient analyte.